LAVAL, QC and PRINCETON, NJ Feb. 18 /CNW/ - Labopharm Inc. (TSX: DDS - News; NASDAQ: DDSS - News) today announced the closing of its previously announced underwritten public offering of 11,764,706 units. The units were sold at a price of US$1.70 per unit for gross proceeds of US$20 million. Net proceeds were US$18,150,000 after deducting underwriting discounts and commissions, and estimated offering expenses.
